ClinicalTrials.gg

Genetic Diseases, Inborn clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 584 studies for Genetic Diseases, Inborn across more than 10 countries. 158 are recruiting or about to start. 148 of them are mainly about Genetic Diseases, Inborn (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its 209 narrower conditions too, such as Cystic Fibrosis: 19,104 studies, 3,792 open.

ClinicalTrials.gov finds 17,096 studies for Genetic Diseases, Inborn. How that becomes 583 here

This page counts the studies the registry files under Genetic Diseases, Inborn, and those it files under no condition that list Genetic Diseases, Inbornthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 17,096Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −15,059Filed under a narrower condition, counted on its own pageCystic Fibrosis 1,550 · Dermatitis, Atopic 1,509 · Anemia, Sickle Cell 1,083 · Hemophilia A 761 · Muscular Dystrophy, Duchenne 464 · Down Syndrome 425 · 177 more
  3. −1List Genetic Diseases, Inborn as a condition, but the registry did not file them under itMost often written as “Rare Fetal Genetic Diseases” (1). The registry filed them under other conditions only, most often Congenital Abnormalities (1) and CHARGE Syndrome (1).
  4. −1,461Match it another way4 name it in the title and 1,457 by a synonym or other text the search reads.
  5. 575Counted here and found by its search
  6. +8
    Counted here, but its search does not find them
  7. 583The count on this page

Status

Completed
286
Recruiting
121
Status unknown
46
Active, not recruiting
44
Terminated
32
Not yet recruiting
18

Phase

Phase 2
117
Phase 3
76
Phase 1
71
Phase 4
8
Early Phase 1
2

Where

United States
297
France
94
United Kingdom
84
Canada
77
Italy
64
Germany
63

Who develops what

Add Genetic Diseases, Inborn to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 17 programs from 16 companies, 0 with this as their studies’ main aim; 9 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Chiesi Farmaceutici, Arrowhead Pharmaceuticals and BioMarin Pharmaceutical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 17 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.infigratinib · BridgeBio · Phase 3 registry mapping onlyNCT06873035 An Interventional Study of Infigratinib in Children With Hypochondroplasia — primary endpoint: Change from baseline (BL) in Annualized Height Velocity (AHV; cm/year) · 24 enrolled
  • 2 Feb 2027 est.VX-670 · Vertex Pharmaceuticals Incorporated · Phase 2 named, not the main aimNCT06185764 A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) — primary endpoint: Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) · 47 enrolled
  • 30 Sept 2027 est.Alpha-1 15% · Grifols · Phase 3 named, not the main aimNCT07555483 A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) — primary endpoint: Steady-state AUC of alpha1-PI over the weekly dosing interval (from 0 to 7 days) (AUC0-7 days) in the IV Treatment Period 1 and in the SC Treatment Period 2 for both dose levels · 40 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Genetic Diseases, Inborn studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · Alkylating agents 5 · Antimetabolites 4 · Corticosteroids 3 · HDAC inhibitors 3

Coming up

47studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger. 86 (71%) take children under 18. 2 (2%) are for women only and 4 (3%) for men only; 28 (23%) take healthy volunteers.

Recruiting studies that take each age, of 121
AgeWomenMen
1065 (54%)67 (55%)
1897 (80%)97 (80%)
3095 (79%)95 (79%)
4088 (73%)88 (73%)
5085 (70%)85 (70%)
6583 (69%)81 (67%)
7576 (63%)74 (61%)
8573 (60%)71 (59%)

Across all 584 studies, recruiting or not: 37% stop at 75 or younger and 34% at 65; 65% take children; 4% are for women only and 7% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Genetic Diseases, Inborn studies take

Of 40 phase 3 interventional studies under Genetic Diseases, Inborn, half reached primary completion within 34 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 16 mo2–20 · 14 studies——
Phase 241 mo19–55 · 25 studies——
Phase 334 mo24–58 · 40 studies34 mo23–58 · 39 studies—
Interventional, no phase41 mo22–60 · 66 studies—41 mo22–60 · 64 studies
Observational110 mo46–193 · 128 studies—124 mo46–… · 94 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 584. Browse all 584 → or search them.